Aziyo Biologics is in talks to divest its orthopedic business, the company said Aug. 14.
The company shared its second quarter financial results along with updates on its operations.
"Our strategy to transform Aziyo into a high growth drug-eluting biomatrix product company continues to move forward," CEO Randy Mills, PhD, said in a news release. "We are in discussions with several interested parties to divest our orthopedics business."
Net sales in the second quarter were $10.3 million, down from $12.6 million in the same time last year. The decrease was largely due to a viable bone matrix recall, which led to a reversal of $3 million in second quarter revenue.